Prognostic and clinicopathological role of soluble programmed cell death ligand-1 in patients with diffuse large B-cell lymphoma: a meta-analysis.

BACKGROUND

The significance of soluble programmed death protein ligand-1 (PD-L1) in predicting the prognosis of diffuse large B-cell lymphoma (DLBCL) has been previously analyzed, but with conflicting results. This study investigated the effect of soluble PD-L1 (sPD-L1) expression on the prognosis of patients with DLBCL.

METHODS

We comprehensively searched the Web of Science, PubMed, Embase, and CNKI databases between their inception and August 14, 2024. The value of sPD-L1 in predicting the overall survival (OS) and progression-free survival (PFS) of patients with DLBCL was analyzed by computing the combined hazard ratios (HRs) and 95% confidence intervals (CIs). Associations between sPD-L1 and the clinicopathological factors of DLBCL were explored by combining odds ratios (ORs) and 95%CIs.

RESULTS

Seven articles involving 826 patients were included in this meta-analysis. Based on our pooled data, elevated sPD-L1 was closely related to poor OS (HR = 2.81, 95%CI = 1.99-3.95, p < 0.001) and inferior PFS (HR = 3.16, 95%CI = 1.41-7.08, p = 0.005) of DLBCL. Moreover, based on the pooled data, higher sPD-L1 was significantly related to the Eastern Cooperative Oncology Group Performance Status Scale (ECOG PS) ≥2 (OR=4.10, 95%CI=1.82-9.24, p=0.001), clinical stage III-IV (OR = 3.30, 95%CI = 1.48-7.39, p = 0.004), elevated lactate dehydrogenase (LDH) levels (OR = 2.14, 95%CI = 1.07-4.30, p = 0.032), and the International Prognostic Index (IPI) score 3-5 (OR = 3.83, 95%CI = 1.91-7.68, p < 0.001) in DLBCL.

CONCLUSION

According to our findings, a higher sPD-L1 level was a significant predictor of poor OS and PFS in patients with DLBCL. Elevated sPD-L1 levels are closely related to factors representing disease aggressiveness in DLBCL.